Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder

Pharmacogenetics and Genomics

Volumn 19, Issue 1, 2009, Pages 67-76

  Ruhé, Henricus G ^a,b   Ooteman, Wendy ^a   Booij, Jan ^a   Michel, Martin C ^a   Moeton, Martina ^a   Baas, Frank ^a   Schene, Aart H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

1231 CIT; Major depressive disorder; Occupancy; Paroxetine; Serotonin transporter; Single photon emission computed tomography; SLC6A4

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG PROTEIN BINDING; FEMALE; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MESENCEPHALON; PRIORITY JOURNAL; PROMOTER REGION; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BASE SEQUENCE; DEPRESSIVE DISORDER, MAJOR; DIENCEPHALON; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; MALE; MESENCEPHALON; MIDDLE AGED; PAROXETINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 58149267603     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32831a6a3a     Document Type: Article

References (58)

1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40.
2. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment J Psychiatry Neurosci 2007; 32:86-102.
3. Erlandsson K, Sivananthan T, Lui D, Spezzi A, Townsend CE, Mu S, et al. Measuring SSRl occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging 2005; 32:1329-1336.
4. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004; 161:826-835.
5. Suhara T, Takano A, Sudo Y, Ichimiya T, lnoue M, Yasuno F, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003; 60:386-391.
6. Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, lkoma Y, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006; 185:395-399.
7. Kent JM, Coplan JD, Lombardo I, Hwang DR, Huang Y, Mawlawi O, et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652. Psychopharmacology (Berl) 2002; 164:341-348.
8. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry 2001;158:1843-1849.
9. Catafau AM, Perez V, Plaza P, Pascual JC, Bullich S, Suarez M, et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a [123I]-ADAM SPECT study. Psychopharmacology (Berl) 2006; 189:145-153.
10. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003; 28:413-420.
11. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 2004; 56:497-502.
12. Mitchell PB. Therapeutic drug monitoring of non-tricyclic antidepressant drugs. Clin Chem Lab Med 2004; 42:1212-1218.
13. Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, et al. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 2008. E-publication doi:10.1038/npp.2008.35.
14. Lesch KP, Gutknecht L Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:1062-1073.
15. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47:643-649.
16. Shioe K, Ichimiya T, Suhara T, Takano A, Sudo Y, Yasuno F, et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 2003; 48:184-188.
17. Van Dyck CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M, et al. Central serotonin transporter availability measured with [1231]β-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004; 161:525-531.
18. Willert M, Stastny J, Pirker W, Praschak-Rieder N, Neumeister A, Asenbaum S, et al. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry 2001; 50:8-12.
19. Schinka JA, Busch RM, Robichaux-Keene N. A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 2004; 9:197-202.
20. Sen S, Burmeister M, Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 2004; 127:85-89.
21. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig lW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386-389.
22. Lotrich FE, Pollock BG. Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 2004; 14:121-129.
23. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297:400-403.
24. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005; 62:146-152.
25. Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 2004; 4:109-123.
26. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulateamygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8:828-834.
27. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12:247-257.
28. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78:815-826.
29. Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, et al. Effect of a triallelic functional polymorphism of the serotonin-transporterlinked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006; 163:48-51.
30. Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [11C] DASB positron emission tomography study. Biol Psychiatry 2007; 62:327-331.
31. Reimold M, Smolka MN, Schumann G, Zimmer A, Wrase J, Mann K, et al. Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J Neural Transm 2007; 114:635-639.
32. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64:783-792.
33. Kraft JB, Peters FJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007; 61:734-742.
34. Ruhe HG, Booij J, Weert HC, Van Reitsma JB, Fransen EJF, Michel MC, et al. Evidence why dose-escalation of paroxetine in major depressive disorder is not effective: a 6-week, randomized-controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2008. E-publication doi:10.1038/npp.2008.148.
35. Van Dyck CH, Malison RT, Seibyl J P, Laruelle M, Klumpp H, Zoghbi SS, et al. Age-related decline in central serotonin transporter availability with [1231]β- CIT SPECT. Neurobiol Aging 2000; 21:497-501.
36. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis l Disorders Patient Edition (SCID-I/P Version. 2.0). Translated in Dutch by Groenestijn MAC, Akkerhuis GW, Kupka RW, Schneider N, Nolen WA 1999. Lisse, the Netherlands, Swets and Zeitlinger BV.
37. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61.
38. Saunders K, Simon G, Bush T, Grothaus L Assessing the feasibility of using computerized pharmacy refill data to monitor antidepressant treatment on a population basis: a comparison of automated and self-report data. J Clin Epidemiol 1998; 51:883-890.
39. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the hamilton depression rating scale. J Psychiatr Res 2000; 34:3-10.
40. Ruhe HG, Dekker JJ, Peen J, Holman R, de Jonghe F. Clinical use of the Hamilton depression rating scale: is increased efficiency possible? A post hoc comparison of Hamilton depression rating scale, Maier and Bech subscales, clinical global impression, and symptom checklist-90 scores. Compr Psychiatry 2005; 46:417-427.
41. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996; 26:477-486.
42. De Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [1231]β-ClT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005; 30:996-1005.
43. Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willert M, et al. Imaging serotonin and dopamine transporters with [1231]β-ClT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000; 41:36-44.
44. Laruelle M, Vanisberg MA, Maloteaux JM. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 1988; 24:299-309.
45. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27:1533-1539.
46. +D report. Am J Psychiatry 2008; 165:342-351.
47. Innis R, Baldwin R, Sybirska E, Zea Y, Laruelle M, al Tikriti M, et al. Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]ClT. Eur J Pharmacol 1991; 200:369-370.
48. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al Tikriti MS, et al. SPECT imaging of dopamine and serotonin transporters with [1231]β- ClT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13:295-309.
49. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRl treatment trial outcome. Boil Psychiatry 2002; 51:723-732.
50. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5:32-38.
51. Smeraldi E, Serretti A, Artioli P, Lorenzi C, Catalano M. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet 2006; 16:153-158.
52. Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O, et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006; 63:978-986.
53. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23:587-590.
54. Kang RH, Wong ML, Choi MJ, Paik JW, Lee MS. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1317-1321.
55. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61:1163-1169.
56. Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:1074-1084.
57. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999; 19:10494-10501.
58. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant- induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 2002; 22:6766-6772.